These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 2787392)
1. Tumor-infiltrating lymphocytes cultured in recombinant interleukin-2: enhancement of growth, cytotoxicity, and phenotypic expression of cytotoxic T-cell antigens by cyclophosphamide given intravenously prior to tumor harvest. Lafreniere R; Borkenhagen K; Bryant LD; Ng E J Biol Response Mod; 1989 Jun; 8(3):238-51. PubMed ID: 2787392 [TBL] [Abstract][Full Text] [Related]
2. Synergistic actions of picibanil (OK-432) on recombinant interleukin-2 induction of tumor-infiltrating lymphocyte expansion, cytotoxicity, and phenotypic differentiation. Lafreniere R; Borkenhagen K; Bryant LD; Ng E; Hayton S J Biol Response Mod; 1990 Feb; 9(1):53-60. PubMed ID: 2181072 [TBL] [Abstract][Full Text] [Related]
3. In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2. Spiess PJ; Yang JC; Rosenberg SA J Natl Cancer Inst; 1987 Nov; 79(5):1067-75. PubMed ID: 3500355 [TBL] [Abstract][Full Text] [Related]
8. Long-term interleukin 2-dependent growth and cytotoxic activity of tumor-infiltrating lymphocytes from human squamous cell carcinomas of the head and neck. Heo DS; Whiteside TL; Johnson JT; Chen KN; Barnes EL; Herberman RB Cancer Res; 1987 Dec; 47(23):6353-62. PubMed ID: 3315186 [TBL] [Abstract][Full Text] [Related]
9. Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity. Belldegrun A; Muul LM; Rosenberg SA Cancer Res; 1988 Jan; 48(1):206-14. PubMed ID: 3257161 [TBL] [Abstract][Full Text] [Related]
10. In vitro enhanced cytotoxicity of tumor-infiltrating lymphocytes transfected with tumor necrosis factor-related apoptosis-inducing ligand and/or interleukin-2 gene in human renal cell carcinoma. Tian JQ; Wang ZP; Rodriguez R; Fu JS; Lu JZ; Ma BL Urology; 2006 May; 67(5):1093-8. PubMed ID: 16635513 [TBL] [Abstract][Full Text] [Related]
11. Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy. Shu SY; Chou T; Rosenberg SA J Immunol; 1987 Jul; 139(1):295-304. PubMed ID: 2953816 [TBL] [Abstract][Full Text] [Related]
12. Expression and function of LFA-1 on A-NK and T-LAK cells: role in tumor target killing and migration into tumor tissue. Donskov F; Basse PH; Hokland M Nat Immun; 1996-1997; 15(2-3):134-46. PubMed ID: 9162263 [TBL] [Abstract][Full Text] [Related]
13. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells. Kalland T; Belfrage H; Bhiladvala P; Hedlund G J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566 [TBL] [Abstract][Full Text] [Related]
14. An improved method for growing murine tumor-infiltrating lymphocytes with in vivo antitumor activity. Yang JC; Perry-Lalley D; Rosenberg SA J Biol Response Mod; 1990 Apr; 9(2):149-59. PubMed ID: 1971302 [TBL] [Abstract][Full Text] [Related]
15. Some characteristics of the cyclophosphamide-induced immunopotentiating cells in the spleen of mice bearing a large MOPC-315 tumor. Mokyr MB; Ye QW Cancer Res; 1985 Oct; 45(10):4932-9. PubMed ID: 4027979 [TBL] [Abstract][Full Text] [Related]
16. Up-regulation of inhibitory natural killer receptors CD94/NKG2A with suppressed intracellular perforin expression of tumor-infiltrating CD8+ T lymphocytes in human cervical carcinoma. Sheu BC; Chiou SH; Lin HH; Chow SN; Huang SC; Ho HN; Hsu SM Cancer Res; 2005 Apr; 65(7):2921-9. PubMed ID: 15805295 [TBL] [Abstract][Full Text] [Related]
17. Immunotherapy of murine hepatic metastases with lymphokine-activated killer cells expanded in serum-free media and recombinant interleukin 2. Lafreniere R; Borkenhagen K; Bryant LD; Huchcroft S Cancer Res; 1989 May; 49(9):2409-14. PubMed ID: 2565160 [TBL] [Abstract][Full Text] [Related]